|2.39||+0.1400||+6.22%||Vol 970.55K||1Y Perf 140.69%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||0.06 2.46%|
|Target Price||6.38||Analyst Rating||Strong Buy 1.00|
|Potential %||166.95||Finscreener Ranking||★★★+ 51.56|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||★ 38.90|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||★+ 41.60|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||84.77||Earnings Rating||Strong Buy|
|Market Cap||159.57M||Earnings Date||6th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.11|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||525.24K|
|Avg. Monthly Volume||314.19K|
|Avg. Quarterly Volume||247.58K|
Aquestive Therapeutics Inc. (NASDAQ: AQST) stock closed at 2.39 per share at the end of the most recent trading day (a 6.22% change compared to the prior day closing price) with a volume of 970.55K shares and market capitalization of 159.57M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Aquestive Therapeutics Inc. CEO is Keith J. Kendall.
The one-year performance of Aquestive Therapeutics Inc. stock is 140.69%, while year-to-date (YTD) performance is 164.94%. AQST stock has a five-year performance of -72.18%. Its 52-week range is between 0.72 and 2.69, which gives AQST stock a 52-week price range ratio of 84.77%
Aquestive Therapeutics Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 14.15, a price-to-sale (PS) ratio of 1.36, a price to cashflow ratio of 38.20, a PEG ratio of -, a ROA of -121.23%, a ROC of -107.70% and a ROE of 84.44%. The company’s profit margin is -91.51%, its EBITDA margin is -112.20%, and its revenue ttm is $37.00 Million , which makes it $0.68 revenue per share.
Of the last four earnings reports from Aquestive Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. Aquestive Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aquestive Therapeutics Inc. is Strong Buy (1), with a target price of $6.38, which is +166.95% compared to the current price. The earnings rating for Aquestive Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aquestive Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aquestive Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 18.44, ATR14 : 0.15, CCI20 : 162.77, Chaikin Money Flow : 0.19, MACD : 0.18, Money Flow Index : 88.67, ROC : 42.26, RSI : 74.25, STOCH (14,3) : 90.32, STOCH RSI : 1.00, UO : 58.93, Williams %R : -9.68), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aquestive Therapeutics Inc. in the last 12-months were:
Tue, 10 Oct 2023 11:01 GMT Analysts Top Healthcare Picks: Aquestive Therapeutics (AQST), Guardant Health (GH)- TipRanks. All rights reserved.
Wed, 20 Sep 2023 19:52 GMT Setback for Neffy unlikely to affect Aquestives Anaphylm, says Alliance Global- TipRanks. All rights reserved.
Tue, 08 Aug 2023 15:25 GMT Aquestive Therapeutics (AQST) Receives a Buy from JMP Securities- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.